CG Oncology (CGON) Financials

CG Oncology’s latest quarter shows a company that remains deeply loss-making, but with a very large cash and investment base that gives it time to execute. In Q1 2026, revenue was just $1.1 million while operating expenses were $64.5 million, leading to a net loss of $60.2 million. That is a wider loss than the prior quarter and reflects that the company is still in heavy development mode rather than commercial scale-up.

The most important positive is liquidity. As of March 31, 2026, CG Oncology reported $33.7 million in cash and $1.04 billion in short-term investments, or about $1.08 billion in total cash and investments. That’s a substantial balance sheet for a clinical-stage biotech and suggests the company has meaningful runway.

• Cash and short-term investments totaled about $1.08 billion at the end of Q1 2026, providing strong financial flexibility.
• The company generated a $392.9 million inflow from financing activities in Q1 2026, largely from common equity issuance, which boosted liquidity.
• Interest and investment income of $6.3 million helped offset some of the operating loss in Q1 2026.
• Total liabilities were only $43.5 million versus $1.09 billion in equity, indicating a very low leverage profile.
• Shareholders’ equity remained strong at $1.09 billion, underscoring the company’s capital position.
• Revenue is still immaterial, with just $1.1 million in Q1 2026 and $2.3 million in Q4 2025, so the business has not yet reached commercial scale.
• Operating cash burn remains substantial, with $56.9 million used in operations in Q1 2026.
• R&D and SG&A expenses remain elevated, which is expected for a biotech advancing its pipeline but also keeps losses high.
• Net loss widened to $60.2 million in Q1 2026 from $41.3 million in Q4 2025, showing the company is still burning cash at a high rate.
• Cash and equivalents fell sharply from $45.1 million in Q3 2025 to $33.7 million in Q1 2026, even though the investment portfolio remains large.

Looking at the last several quarters, CG Oncology has shown a consistent pattern typical of an early-stage biotech: small or negligible revenue, high operating losses, and heavy investment in research and development. Quarterly operating losses have ranged from roughly $14 million to more than $66 million, while R&D spending has often been the largest expense line.

There are also signs that the company’s cash position has been actively managed through its investment portfolio and equity raises. In prior quarters, CG Oncology repeatedly sold investments to fund operations, and it also raised capital through share issuance. That is common for pre-commercial biotech companies, but investors should watch dilution closely.

Balance sheet trend: Total assets jumped from $729.9 million in Q3 2025 to $1.14 billion in Q1 2026, mostly because of the shift into cash and short-term investments. At the same time, liabilities stayed modest, rising only to $43.5 million. That combination gives the company a strong near-term financial cushion.

Bottom line: CG Oncology’s financials show a company with excellent liquidity but no meaningful profitability yet. The key investor question is whether its large cash balance can support enough clinical and commercial progress to justify the ongoing burn rate. For now, the balance sheet is a major strength, but earnings and operating cash flow remain clearly negative.